
Sign up to save your podcasts
Or
Big tech taking the lead, and driving the S&P 500 and Nasdaq to fresh record highs. How semis, software, and other sections of the tech trade can fuel your portfolio. Plus Fast Money’s Obesity Week coverage continues. Eli Lilly’s Chief Scientific Officer breaks down how the company’s obesity drug Zepbound performed in its first head-to-head clinical trial against Novo’s Wegovy, and what the results could mean for the weight loss drug wars.
Fast Money Disclaimer
3.9
12371,237 ratings
Big tech taking the lead, and driving the S&P 500 and Nasdaq to fresh record highs. How semis, software, and other sections of the tech trade can fuel your portfolio. Plus Fast Money’s Obesity Week coverage continues. Eli Lilly’s Chief Scientific Officer breaks down how the company’s obesity drug Zepbound performed in its first head-to-head clinical trial against Novo’s Wegovy, and what the results could mean for the weight loss drug wars.
Fast Money Disclaimer
4,082 Listeners
495 Listeners
238 Listeners
3,179 Listeners
147 Listeners
326 Listeners
67 Listeners
153 Listeners
2,116 Listeners
2,068 Listeners
596 Listeners
544 Listeners
20 Listeners
198 Listeners
403 Listeners
302 Listeners
116 Listeners
803 Listeners
180 Listeners
60 Listeners
157 Listeners
21 Listeners
34 Listeners
16 Listeners
9 Listeners
262 Listeners
15 Listeners